Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 2

3(33.3%)

Early Phase 1

1(11.1%)

Phase 3

1(11.1%)

9Total

Phase 1(4)

Phase 2(3)

Early Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07407634Early Phase 1Not Yet Recruiting

A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.

Role: lead

NCT07300488Phase 2Active Not Recruiting

Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Role: lead

NCT07203118Phase 2Active Not Recruiting

A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B

Role: lead

NCT06280534Phase 1Unknown

Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects

Role: lead

NCT06141109Phase 1Unknown

Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma

Role: lead

NCT06141096Phase 2Unknown

MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma

Role: lead

NCT06122454Phase 1Unknown

A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB

Role: lead

NCT04543565Phase 3Unknown

Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study

Role: lead

NCT04277897Phase 1Unknown

A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers.

Role: lead

All 9 trials loaded